Search results for "SHI"

showing 3 items of 9733 documents

Skutki śmierci wszystkich wspólników spółki jawnej w spółce przewidującej wstąpienie do niej spadkobierców

2021

Pursuant to Art. 58 § 1 point 4 of the Code of Commercial Companies dissolution of a general partnership results in the death of the partner of the general partnership. The dissolution of a general partnership starts the process of its liquidation, unless the partners agree on a different method of terminating its activity. The provision of art. 58 § 1 point 4 of the Code of Commercial Companies however, it is a dispositive legal norm, which means that the articles of association of a general partnership may stipulate that the death of a partner is not a basis for its termination. With the death of all partners, the general partnership undoubtedly becomes a kind of real hybrid. The represen…

śmierć wszystkich wspólnikówdeath of all partnersgeneral partnershipdziedziczenieinheritancerozwiązanie i likwidacja spółki jawnejdissolution and liquidation of the general partnershipspółka jawnaRejent
researchProduct

Monotherapy with indacaterol once daily reduces the rate of exacerbations in patients with moderate-to-severe COPD: Post-hoc pooled analysis of 6 mon…

2014

Summary Background In patients with COPD, exacerbations are associated with poor quality of life and may shorten survival. Prevention of exacerbations is, therefore, a key objective in COPD management. Indacaterol, a once-daily ultra-long-acting β 2 -agonist, has been shown to reduce exacerbations in various studies. This pooled analysis evaluated the effect of indacaterol on exacerbations versus placebo. Methods Six-month data were pooled from three randomized, double-blind, and placebo-controlled studies: indacaterol 300 μg versus placebo (1 year); indacaterol 150 μg and 300 μg versus placebo (6 months); and indacaterol 150 μg versus placebo (6 months). All treatments were administered on…

β2-agonistPulmonary and Respiratory Medicinemedicine.medical_specialtyExacerbationKaplan-Meier EstimateQuinolonesPlaceboDrug Administration SchedulePooled analysisExacerbationsPulmonary Disease Chronic ObstructiveFEV1/FVC ratioDouble-Blind MethodForced Expiratory VolumeInternal medicineHumansCOPDMedicineAdrenergic beta-2 Receptor AgonistsRandomized Controlled Trials as TopicIndacaterolCOPDDose-Response Relationship Drugbusiness.industryMinimal clinically important differenceHazard ratiomedicine.diseaseConfidence intervalBronchodilator AgentsClinical Trials Phase III as TopicAnesthesiaIndansIndacaterolbusinessBronchodilatormedicine.drugRespiratory Medicine
researchProduct

The “Diabetes Comorbidome”: A Different Way for Health Professionals to Approach the Comorbidity Burden of Diabetes

2022

(1) Background: The disease burden related to diabetes is increasing greatly, particularly in older subjects. A more comprehensive approach towards the assessment and management of diabetes’ comorbidities is necessary. The aim of this study was to implement our previous data identifying and representing the prevalence of the comorbidities, their association with mortality, and the strength of their relationship in hospitalized elderly patients with diabetes, developing, at the same time, a new graphic representation model of the comorbidome called “Diabetes Comorbidome”. (2) Methods: Data were collected from the RePoSi register. Comorbidities, socio-demographic data, severity and comorbidit…

“Diabetes Comorbidome”Health Information ManagementLeadership and ManagementHealth Policy“Diabetes Comorbidome”; comorbidities; dementia; cancer; in-hospital mortality; 3-month mortality; 1-year mortality1-year mortality3-month mortalitycancerHealth Informatics1-year mortality 3-month mortality cancer comorbidities dementia in-hospital mortality “Diabetes Comorbidome”comorbiditiesdementiain-hospital mortality
researchProduct